Impact of Evolocumab on the Antiplatelet Effects of Ticagrelor and Aspirin in Patients With Acute Coronary Syndrome

Sponsor
First Affiliated Hospital of Harbin Medical University
Study ID
NCT05418166
Status
Unknown

Conditions

  • Acute Coronary Syndrome

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Evolocumab — DRUG
    evolocumab 140mg subcutaneous injection after regular take Ticagrelor and Aspirin for 5 days.

Study Details

The aim of the present study is to investigate the effects of evolocumab in addition to statin therapy on platelet reactivity in patients with acute coronary syndrome (ACS) while on Ticagrelor and Aspirin treatment.

Key Dates

Start date
Dec 23, 2021
Status verified
Apr 2022
Primary completion
Sep 1, 2022
Completion
Sep 1, 2022

Study Design

Enrollment
30 participants (estimated)

Arms

  • Arm: pro-Evo
    Patients regularly take Ticagrelor and Aspirin for five days.Platelet activity was test before inject Evolocumab.
  • Arm: 24h-Evo
    Patients regularly take Ticagrelor and Aspirin for five days, then inject Evolocumab 140mg. Platelet activity was test 24h after inject.
  • Arm: 1w-Evo
    Patients regularly take Ticagrelor and Aspirin for five days, then inject Evolocumab 140mg. Platelet activity was test 1 week after inject.

Primary Outcome Measure

Platelet Reactivity Defined by VerifyNow PU in Patients diagnosed ACS [ Time Frame: 1 week ]

Central Contacts

Related Studies